Equities analysts forecast that AmerisourceBergen Corp. (NYSE:ABC) will announce $43.68 billion in sales for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for AmerisourceBergen’s earnings. The lowest sales estimate is $43.50 billion and the highest is $44.07 billion. AmerisourceBergen reported sales of $41.03 billion in the same quarter last year, which indicates a positive year over year growth rate of 6.5%. The company is scheduled to report its next quarterly earnings results on Wednesday, May 1st.

On average, analysts expect that AmerisourceBergen will report full-year sales of $180.20 billion for the current financial year, with estimates ranging from $178.12 billion to $183.24 billion. For the next fiscal year, analysts forecast that the company will post sales of $188.69 billion, with estimates ranging from $186.10 billion to $192.25 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover AmerisourceBergen.

AmerisourceBergen (NYSE:ABC) last announced its quarterly earnings results on Thursday, January 31st. The company reported $1.60 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.10. The company had revenue of $45.39 billion for the quarter, compared to analyst estimates of $43.52 billion. AmerisourceBergen had a net margin of 0.69% and a return on equity of 44.53%.

ABC has been the topic of several recent analyst reports. ValuEngine upgraded shares of AmerisourceBergen from a “sell” rating to a “hold” rating in a research note on Thursday, January 31st. Zacks Investment Research upgraded shares of AmerisourceBergen from a “sell” rating to a “hold” rating in a research note on Thursday, November 22nd. TheStreet lowered shares of AmerisourceBergen from a “b-” rating to a “c+” rating in a research note on Tuesday, January 8th. Finally, UBS Group initiated coverage on shares of AmerisourceBergen in a research note on Thursday, January 17th. They issued a “buy” rating and a $89.00 price target on the stock. Two research analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $88.33.

In other news, CEO Steven H. Collis sold 21,344 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $83.62, for a total transaction of $1,784,785.28. Following the transaction, the chief executive officer now directly owns 155,923 shares in the company, valued at $13,038,281.26. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Steven H. Collis sold 21,350 shares of the firm’s stock in a transaction that occurred on Wednesday, January 2nd. The stock was sold at an average price of $73.96, for a total transaction of $1,579,046.00. Following the transaction, the chief executive officer now owns 155,929 shares in the company, valued at $11,532,508.84. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 109,862 shares of company stock worth $8,934,873. Insiders own 27.80% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Acima Private Wealth LLC purchased a new position in shares of AmerisourceBergen during the fourth quarter worth approximately $26,000. Private Capital Group LLC grew its position in shares of AmerisourceBergen by 201.3% during the fourth quarter. Private Capital Group LLC now owns 482 shares of the company’s stock worth $36,000 after acquiring an additional 322 shares during the last quarter. JNBA Financial Advisors purchased a new position in shares of AmerisourceBergen during the fourth quarter worth approximately $37,000. Financial Gravity Companies Inc. purchased a new position in shares of AmerisourceBergen during the fourth quarter worth approximately $54,000. Finally, Exane Asset Management purchased a new position in shares of AmerisourceBergen during the fourth quarter worth approximately $73,000. Institutional investors and hedge funds own 66.29% of the company’s stock.

AmerisourceBergen stock traded up $0.67 during mid-day trading on Friday, hitting $80.18. The company had a trading volume of 2,009,349 shares, compared to its average volume of 1,511,942. The firm has a market capitalization of $16.78 billion, a P/E ratio of 12.35, a P/E/G ratio of 1.45 and a beta of 1.13. AmerisourceBergen has a 1 year low of $69.36 and a 1 year high of $98.23. The company has a quick ratio of 0.53, a current ratio of 0.94 and a debt-to-equity ratio of 1.43.

The firm also recently announced a quarterly dividend, which was paid on Monday, March 4th. Stockholders of record on Tuesday, February 19th were given a dividend of $0.40 per share. The ex-dividend date of this dividend was Friday, February 15th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.00%. AmerisourceBergen’s dividend payout ratio (DPR) is presently 24.65%.

AmerisourceBergen Company Profile

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.

Featured Story: What are retained earnings?

Get a free copy of the Zacks research report on AmerisourceBergen (ABC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AmerisourceBergen (NYSE:ABC)

Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.